Monitoring Drug Safety in Pregnancy with Scan Statistics: A Comparison of Two Study Designs.


Journal

Epidemiology (Cambridge, Mass.)
ISSN: 1531-5487
Titre abrégé: Epidemiology
Pays: United States
ID NLM: 9009644

Informations de publication

Date de publication:
01 01 2023
Historique:
pubmed: 18 10 2022
medline: 6 12 2022
entrez: 17 10 2022
Statut: ppublish

Résumé

Traditional surveillance of adverse infant outcomes following maternal medication exposures relies on pregnancy exposure registries, which are often underpowered. We characterize the statistical power of TreeScan, a data mining tool, to identify potential signals in the setting of perinatal medication exposures and infant outcomes. We used empirical data to inform background incidence of major congenital malformations and other birth conditions. Statistical power was calculated using two probability models compatible with TreeScan, Bernoulli and Poisson, while varying the sample size, magnitude of the risk increase, and incidence of a specified outcome. We also simulated larger referent to exposure matching ratios when using the Bernoulli model in the setting of fixed N:1 propensity score matching. Finally, we assessed the impact of outcome misclassification on power. The Poisson model demonstrated greater power to detect signals than the Bernoulli model across all scenarios and suggested a sample size of 4,000 exposed pregnancies is needed to detect a twofold increase in risk of a common outcome (approximately 8 per 1,000) with 85% power. Increasing the fixed matching ratio with the Bernoulli model did not reliably increase power. An outcome definition with high sensitivity is expected to have somewhat greater power to detect signals than an outcome definition with high positive predictive value. Use of the Poisson model with an outcome definition that prioritizes sensitivity may be optimal for signal detection. TreeScan is a viable method for surveillance of adverse infant outcomes following maternal medication use.

Sections du résumé

BACKGROUND
Traditional surveillance of adverse infant outcomes following maternal medication exposures relies on pregnancy exposure registries, which are often underpowered. We characterize the statistical power of TreeScan, a data mining tool, to identify potential signals in the setting of perinatal medication exposures and infant outcomes.
METHODS
We used empirical data to inform background incidence of major congenital malformations and other birth conditions. Statistical power was calculated using two probability models compatible with TreeScan, Bernoulli and Poisson, while varying the sample size, magnitude of the risk increase, and incidence of a specified outcome. We also simulated larger referent to exposure matching ratios when using the Bernoulli model in the setting of fixed N:1 propensity score matching. Finally, we assessed the impact of outcome misclassification on power.
RESULTS
The Poisson model demonstrated greater power to detect signals than the Bernoulli model across all scenarios and suggested a sample size of 4,000 exposed pregnancies is needed to detect a twofold increase in risk of a common outcome (approximately 8 per 1,000) with 85% power. Increasing the fixed matching ratio with the Bernoulli model did not reliably increase power. An outcome definition with high sensitivity is expected to have somewhat greater power to detect signals than an outcome definition with high positive predictive value.
CONCLUSIONS
Use of the Poisson model with an outcome definition that prioritizes sensitivity may be optimal for signal detection. TreeScan is a viable method for surveillance of adverse infant outcomes following maternal medication use.

Identifiants

pubmed: 36252086
doi: 10.1097/EDE.0000000000001561
pii: 00001648-202301000-00012
doi:

Types de publication

Journal Article Research Support, U.S. Gov't, P.H.S.

Langues

eng

Sous-ensembles de citation

IM

Pagination

90-98

Subventions

Organisme : FDA HHS
ID : HHSF223201400030I
Pays : United States

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Déclaration de conflit d'intérêts

The authors report no conflicts of interest.

Références

Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. Postapproval Pregnancy Safety Studies, Guidance for Industry, Draft Guidance. 2019. Available at: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/postapproval-pregnancy-safety-studies-guidance-industry . Accessed: November 1, 2020.
Bird ST, Gelperin K, Taylor L, et al. Enrollment and retention in 34 United States pregnancy registries contrasted with the manufacturer’s capture of spontaneous reports for exposed pregnancies. Drug Saf. 2018;41:87–94.
Gelperin K, Hammad H, Leishear K, et al. A systematic review of pregnancy exposure registries: examination of protocol-specified pregnancy outcomes, target sample size, and comparator selection. Pharmacoepidemiol Drug Saf. 2017;26:208–214.
Kulldorff M, Fang Z, Walsh SJ. A tree-based scan statistic for database disease surveillance. Biometrics. 2003;59:323–331.
Kulldorff M, Dashevsky I, Avery TR, et al. Drug safety data mining with a tree-based scan statistic. Pharmacoepidemiol Drug Saf. 2013;22:517–523.
McClure DL, Raebel MA, Yih WK, et al. Mini-Sentinel methods: framework for assessment of positive results from signal refinement. Pharmacoepidemiol Drug Saf. 2014;23:3–8.
Wang SV, Maro JC, Baro E, et al. Data mining for adverse drug events with a propensity score-matched tree-based scan statistic. Epidemiology. 2018;29:895–903.
Huybrechts KF, Kulldorff M, Hernandez-Diaz S, et al. Active surveillance of the safety of medications used in pregnancy. AJE. 2021;190:1159–1168.
Wang S, Gagne J, Maro J, et al. A general propensity score for signal detection using tree-based scan statistics. Pharmacoepidemiol Drug Saf. 2019;28(S2):29.
Yih WK, Maro JC, Nguyen M, et al. Assessment of quadrivalent human papillomavirus vaccine safety using the self-controlled tree-temporal scan statistic signal-detection method in the sentinel system. Am J Epidemiol. 2018;187:1269–1276.
Yih WK, Kulldorff M, Dashevsky I, et al. Using the self-controlled tree-temporal scan statistic to assess the safety of live attenuated herpes zoster vaccine. Am J Epidemiol. 2019;188:1383–1388.
Yih WK, Kulldorff M, Dashevsky I, et al. A broad safety assessment of the recombinant herpes zoster vaccine. Am J Epidemiol. 2022;191:957–964.
Maro JC, Dashevsky I, Kulldorff M. Postlicensure Medical Product Safety Data Mining: Power Calculations for Bernoulli Data. Available at: https://www.sentinelinitiative.org/studies/vaccines-blood-biologics/postlicensure-medical-product-safety-data-mining-power . Accessed: November 1, 2020.
Maro JC, Nguyen MD, Dashevsky I, et al. Statistical power for postlicensure medical product safety data mining. eGEMs 2017;5:17.
Austin PC. Statistical criteria for selecting the optimal number of untreated subjects matched to each treated subject when using many-to-one matching on the propensity score. Am J Epidemiol. 2010;172:1092–1097.
Chubak J, Pocobelli G, Weiss NS. Tradeoffs between accuracy measures for electronic health care data algorithms. J Clin Epidemiol. 2012;65:343–349.e2.
Maro JC, Brown JS, Dal Pan GJ, et al. Minimizing signal detection time in postmarket sequential analysis: balancing positive predictive value and sensitivity. Pharmacoepidemiol Drug Saf. 2014;23:839–848.
Austin PC. The relative ability of different propensity score methods to balance measured covariates between treated and untreated subjects in observational studies. Med Decis Making. 2009;29:661–677.
Li L, Kulldorff M. A conditional maximized sequential probability ratio test for Pharmacovigilance. Stat Med. 2010;29:284–295.

Auteurs

Elizabeth A Suarez (EA)

From the Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.

Michael Nguyen (M)

Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

Di Zhang (D)

Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

Yueqin Zhao (Y)

Office of Biostatistics, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

Danijela Stojanovic (D)

Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

Monica Munoz (M)

Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

Jane Liedtka (J)

Division of Pediatric and Maternal Health, Center for Drug and Evaluation Research, US Food and Drug Administration, Silver Spring, MD.

Abby Anderson (A)

Division of Urology, Obstetrics and Gynecology, Center for Drug and Evaluation Research, US Food and Drug Administration, Silver Spring, MD.

Wei Liu (W)

Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, MD.

Inna Dashevsky (I)

From the Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.

Sandra DeLuccia (S)

From the Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.

Talia Menzin (T)

From the Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.

Jennifer Noble (J)

From the Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.

Judith C Maro (JC)

From the Department of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, MA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH